Acadian Asset Management
NBRV

Acadian Asset Management’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Acadian Asset Management’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-8
Closed -$24K – 1678
2017
Q1 		$24K Buy
+8
New +$19.5K ﹤0.01% 1349

Other funds holding NBRV

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Acadian Asset Management's NBRV Position: Q2 2017 in Review

Acadian Asset Management sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q2 2017, closing a stake of 8 shares — an estimated $24K sold.

Acadian Asset Management first reported a position in NBRV in Q1 2017 and held it in 1 quarter. The position peaked at $24K in Q1 2017. 23 funds tracked by Wall St. Rank hold NBRV as of Q2 2017.

  • Acadian Asset Management reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q2 2017 after selling out during the quarter.
  • Acadian Asset Management sold 8 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q2 2017, an estimated $24K.
  • Acadian Asset Management first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q1 2017 and held it in 1 quarter.
  • Acadian Asset Management's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $24K in Q1 2017.
  • 23 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q2 2017.

Based on Acadian Asset Management's 13F filing for Q2 2017, filed 25 Jul 2017.